- Country: USA
- Summary: Novel Assays to Address Translational Gaps in Treatment Development (Ug3/Uh3 Clinical Trial Optional)
- UST Ref No: 68706068
- Deadline: 20 Jun 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: PAR-22-169
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Tender are invited for Novel Assays to Address Translational Gaps in Treatment Development (UG3/UH3 Clinical Trial Optional)
CFDA Number : 93.242 -- Mental Health Research Grants
Cost Sharing or Matching Requirement : No
Closing Date for Applications: Jun 20, 2025
Posted Date : Jul 07, 2022
Description: The overall goal of this initiative is to identify neurophysiological measures potential assays for treatment development research. The funding opportunity announcement (FOA) will support efforts to optimize and evaluate measures of neurophysiological processes that are disrupted within or across mental disorders in both healthy humans and in another species relevant to the therapeutic development pipeline. The initiative will support initial proof of concept studies aimed at identifying measures for potential development as preclinical assays for evaluating potential new drug and device therapies and their targets. Data will also reveal assay measures where the performance between preclinical animal species and humans is dissimilar, thus establishing a firm basis for limiting speculative extrapolations of preclinical animal findings to humans. The ultimate practical goal of this FOA is to improve the efficiency of the therapeutic development process by identifying coherence of measures and inconsistencies between the preclinical screening pipeline and clinical evaluation of new treatment candidates and thereby hasten the ... - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINNovel Assays to Address Translational Gaps in Treatment Development (Ug3/Uh3 Clinical Trial Optional) - USA Tender
The NATIONAL INSTITUTES OF HEALTH, a Government sector organization in USA, has announced a new tender for Novel Assays to Address Translational Gaps in Treatment Development (Ug3/Uh3 Clinical Trial Optional). This tender is published on USARFP under UST Ref No: 68706068 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-06-20.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
